Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) moved to tighten its grip on one of biotech’s hottest disease areas, striking a $50.00 million licensing deal with Pfizer that could …
Madrigal’s $50M Pfizer Deal Sparks a New MASH Drug Power Play Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it granted equity inducement awards to four newly hired non-executive employees, a move that highlights the company’s effort to attract talent …
Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it will present at the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026, placing the company before investors at …
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has issued a new round of equity inducement awards to 24 non-executive employees, strengthening its talent base as the company advances commercial …
Madrigal Pharmaceuticals Expands Workforce With New Equity Grants to Staff Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) granted new equity awards this month to three recently hired non-executive employees, signaling continued growth as the company advances its commercial and …
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), the company behind the first FDA- and European Commission–approved drug for MASH, will spotlight its flagship therapy in a pair of fireside …
Biopharma Giant Draws Spotlight With High-Stakes Investor Talks on MASH Breakthrough Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) unveiled new two-year data showing that its flagship therapy Rezdiffra produced sustained improvements in patients with compensated MASH cirrhosis, a population with …
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has granted equity awards to 18 new non-executive employees as part of its 2025 Inducement Plan, reinforcing the biopharmaceutical company’s strategy to …
Madrigal Pharmaceuticals Expands Team With Equity Awards to New Hires Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported strong third-quarter 2025 results, fueled by accelerating sales of its liver disease drug Rezdiffra™ (resmetirom) and a major expansion of its …
Madrigal Posts Soaring Rezdiffra Sales, Expands Pipeline With GLP-1 Partnership Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that it will present multiple new analyses on its MASH therapy, Rezdiffra (resmetirom), at the upcoming American Association for the Study …
Madrigal to Unveil New Rezdiffra Data at Key Liver Disease Conference Read More